Christian Angermayer is an entrepreneur and investor and the founder of Apeiron Investment Group, his family office and merchant banking business. Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate & Prop-Tech. Apeiron completes deals across the entire lifecycle and balance sheet of a company, from non-listed Seed/Start Up investments to larger scale Restructuring and Special Situations deals (mostly listed), and additionally also invests in venture and private equity funds.
In 2000, Christian co-founded Ribopharma (original patents for RNAi technology) which merged with stock market listed US SPAC Alnylam in 2003 and has a $13bn market cap today. Since then, Christian has created, co-founded and invested in numerous successful companies, has raised over $2bn for his portfolio companies and has been involved in more than 50 successful IPO- and M&A-transactions either as an entrepreneur, investor or banker/advisor.
Today, Christian is one of the most active and significant investors in European fintech companies with a special focus on crypto-currencies and blockchain-related business models. Apeiron’s cryptocurrency investments are mainly done via its subsidiary Cryptology Asset Group PLC. Among various other investments, Cryptology is the largest institutional shareholder of Block.One, the company behind EOS, one of the most successful protocol tokens.
With his biotech company atai Life Sciences, Christian has the ambitious goal to develop solutions for the more than 300 million people who suffer from depression, especially by bringing back formerly vilified drugs like psychedelics into the legal realm. With his biotech companies Rejuveron and Cambrian, Christian is developing drugs and technologies which have the potential to significantly prolong human life span and ultimately defeat death.
In addition to his entrepreneurial activities, Christian places great value on social, political and societal commitments. He is a Young Global Leader of the World Economic Forum, a member of the Presidential Advisory Council of His Excellency President Paul Kagame of Rwanda and a member of the Milken Institute Young Leaders Circle. Christian is a board member of Vienna-based Hayek Institute, a Libertarian and free-markets-focused think-tank and a member of The Court of the London School of Hygiene and Tropical Medicine.
Christian’s “Angermayer Policy and Innovation Forum” convenes several times a year Head of States, leading politicians, investors and scientists to discuss crucial topics and issues.
Passionate about the arts and film, Christian has (executive) produced 21 feature films including critically acclaimed movies like Filth, Aspern Papers and Hector And The Search For Happiness. He is the largest shareholder of DEAG, the largest live entertainment company in Europe, producing over 4,500 shows per year from pop to classic and from exhibitions to family entertainment. Christian has a unique art collection centred around the theme “Psychedelics / Entheogens”.
How old is Christian Angermayer?
Mr. Angermayer is currently 46 years old. There are 6 older executives and no younger executives at Atai Life Sciences. The oldest executive at Atai Life Sciences is Dr. Srinivas G. Rao M.D., Ph.D., Co-Founder & Co-CEO, who is 55 years old. Learn More on Christian Angermayer's age.
How do I contact Christian Angermayer?
Has Christian Angermayer been buying or selling shares of Atai Life Sciences?
Who are Atai Life Sciences' active insiders?
Are insiders buying or selling shares of Atai Life Sciences?
During the last year, insiders at the sold shares 4 times. They sold a total of 2,900,353 shares worth more than $16,548,244.26. The most recent insider tranaction occured on September, 26th when Major Shareholder Life Sciences N.V. Atai sold 2,660,000 shares worth more than $16,093,000.00. Insiders at Atai Life Sciences own 31.2% of the company.
Learn More about insider trades at Atai Life Sciences. Information on this page was last updated on 9/26/2024.